Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel. The drugs differ in pharmacodynamics and platelet rea...
Saved in:
Main Authors: | T. M. Uskach, A. S. Tereshchenko |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2020-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2361 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01) -
The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01) -
Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01) -
Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
by: A. I. Sapina, et al.
Published: (2024-04-01)